Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

264.96
+3.131.20%
Post-market: 266.401.44+0.54%19:59 EDT
Volume:5.16M
Turnover:1.37B
Market Cap:468.29B
PE:74.85
High:266.84
Open:260.70
Low:260.10
Close:261.83
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.05
T/O Rate:0.29%
Dividend:6.83
Dividend Rate:2.58%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-78.90
PE(LYR):112.27

Loading ...

Basilea Publishes Investor Presentation on Anti-Infectives Strategy, Pipeline and Hospital Brands Cresemba, Zevtera

Reuters
·
Aug 05

Market Chatter: AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition

MT Newswires Live
·
Aug 05

AbbVie Launches $10 Billion Bond Sale to Fund Apogee Acquisition, Bloomberg Reports

MT Newswires Live
·
Aug 05

Abbvie Seeks at Least $8 Billion in Debt to Fund Apogee Deal - Bloomberg News

THOMSON REUTERS
·
Aug 04

Abbvie Files for Nine-Part Senior Notes Offering; Size not Disclosed- SEC Filing

THOMSON REUTERS
·
Aug 04

Abbvie : Plans to Use Note Offering Proceeds for Apogee Therapeutics Acquisition Funding

THOMSON REUTERS
·
Aug 04

AbbVie Says FDA Accepts BOTOX Cosmetic sBLA for Masseter Muscle Prominence Indication

Reuters
·
Aug 04

Abbvie - Phase 3 Studies Met Primary Endpoints with Statistically Significant Improvements Versus Placebo

THOMSON REUTERS
·
Aug 04

Abbvie - Safety Profile Consistent with Established Uses; no New Safety Signals Identified

THOMSON REUTERS
·
Aug 04

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for Botox® Cosmetic for Masseter Muscle Prominence

THOMSON REUTERS
·
Aug 04

AbbVie price target raised to $288 from $261 at Guggenheim

TIPRANKS
·
Aug 04

Abbvie - Ubrelvy Receives Positive Recommendation from Canada's Drug Agency for Migraine Treatment

THOMSON REUTERS
·
Aug 04

Defence Therapeutics Names Amie Phinney CEO, Plouffe Becomes Executive Chairman

Reuters
·
Aug 04

AbbVie Inc. Stock Underperforms Monday When Compared to Competitors

Dow Jones
·
Aug 04

AbbVie’s ABBV-706 Lung Cancer Trial: A New Late-Stage Bet in Small Cell Oncology

TIPRANKS
·
Aug 04

AbbVie’s RAMpUp Study Targets Real-World Edge in Atopic Dermatitis

TIPRANKS
·
Aug 04

AbbVie Pipeline Draws Greater Investor Focus After 'Strong' Q2, RBC Says

MT Newswires Live
·
Aug 03

AbbVie is Maintained at Overweight by Cantor Fitzgerald

Dow Jones
·
Aug 03

Canaccord Genuity Adjusts AbbVie Price Target to $290 From $282, Maintains Buy Rating

MT Newswires Live
·
Aug 03

AbbVie price target raised to $285 from $265 at Cantor Fitzgerald

TIPRANKS
·
Aug 03